BACKGROUND:Polyurethane materials,with their outstanding physicochemical properties,present extensive opportunities in the realm of biomedical engineering.Biomimetic design and functional modification of polyurethane nerve conduits are expected to further address the challenges of nerve regeneration and repair.OBJECTIVE:To review the current status and advancements in the application of polyurethane-based nerve conduits in the field of peripheral nerve repair.METHODS:The Chinese and English search terms consisted of"polyurethane,PU,polyurethane material,polyurethane biomaterials,nerve regeneration,peripheral nerve injury,nerve repair,nerve scaffold,nerve guidance conduit,nerve conduits."The search was conducted in databases such as PubMed,Web of Science,CNKI(China National Knowledge Infrastructure),and WanFang for articles published from 2014 to 2024.Finally,61 articles were included in the review.RESULTS AND CONCLUSION:Biomimetic composition is an effective strategy for enhancing the biological activity of polyurethane nerve conduits.Through structural biomimicry,polyurethane nerve conduits can be optimized to provide biological guidance cues for neural tissue regeneration.The biomechanically biomimetic polyurethane nerve conduits are likely to play a significant role in immune modulation and the promotion of axonal growth.By optimizing the conductive microenvironment of polyurethane materials,the reconstruction of neural electrical signal pathways can be facilitated.Polyurethane nerve conduits can serve as drug carriers,exerting anti-inflammatory and neuroprotective effects.Although the combined application of multiple design strategies can improve various aspects of damaged nerve function,the complex structure and dynamically changing pathophysiological microenvironment of nerves mean that nerve conduit design strategies still require refinement.Future advancements and innovations in nerve biomimetic design strategies hold promise for providing new insights and opportunities in the field of neural tissue engineering.

BACKGROUND:Polyurethane materials,with their outstanding physicochemical properties,present extensive opportunities in the realm of biomedical engineering.Biomimetic design and functional modification of polyurethane nerve conduits are expected to further address the challenges of nerve regeneration and repair.OBJECTIVE:To review the current status and advancements in the application of polyurethane-based nerve conduits in the field of peripheral nerve repair.METHODS:The Chinese and English search terms consisted of"polyurethane,PU,polyurethane material,polyurethane biomaterials,nerve regeneration,peripheral nerve injury,nerve repair,nerve scaffold,nerve guidance conduit,nerve conduits."The search was conducted in databases such as PubMed,Web of Science,CNKI(China National Knowledge Infrastructure),and WanFang for articles published from 2014 to 2024.Finally,61 articles were included in the review.RESULTS AND CONCLUSION:Biomimetic composition is an effective strategy for enhancing the biological activity of polyurethane nerve conduits.Through structural biomimicry,polyurethane nerve conduits can be optimized to provide biological guidance cues for neural tissue regeneration.The biomechanically biomimetic polyurethane nerve conduits are likely to play a significant role in immune modulation and the promotion of axonal growth.By optimizing the conductive microenvironment of polyurethane materials,the reconstruction of neural electrical signal pathways can be facilitated.Polyurethane nerve conduits can serve as drug carriers,exerting anti-inflammatory and neuroprotective effects.Although the combined application of multiple design strategies can improve various aspects of damaged nerve function,the complex structure and dynamically changing pathophysiological microenvironment of nerves mean that nerve conduit design strategies still require refinement.Future advancements and innovations in nerve biomimetic design strategies hold promise for providing new insights and opportunities in the field of neural tissue engineering.

Objective:To analyze the risk factors of pulmonary thromboembolism (PTE) in patients with pulmonary tuberculosis (PTB), to improve the awareness of clinicians.Methods:A total of 120 PTB patients complicated with PTE (PTE group) and 120 PTB patients without PTB (control group) admitted to the Affiliated Hospital of Zunyi Medical University from January 2018 to December 2022 were included. Clinical data from both groups were collected and compared. Statistical analyses were performed using the chi-square tests and Mann-Whitney U test, and binary logistic regression analysis was performed to identify the risk factors for PTE in PTB patients. Results:The age of the PTE group was 69.00(63.00, 76.75) years. The rates of comorbid chronic pulmonary diseases, respiratory failure, and diabetes in PTE group were 40.00%(48/120), 24.17%(29/120), and 12.50%(15/120), respectively.The incidence rates of dyspnea, chest distress, chest pain, and palpitations in PTE group were 80.83%(97/120), 21.67%(26/120), 23.33%(28/120), and 10.00%(12/120), respectively. The D-dimer level in PTE group was 3.34 (2.05, 6.60) mg/L. These results were all higher than those in the control group (10.00%(12/120), 7.50%(9/120), 3.33%(4/120), 36.67%(44/120), 6.67%(8/120), 13.33%(16/120), 3.33%(4/120), and 0.97(0.41, 2.11) mg/L, respectively). The differences were all statistically significant ( χ2=28.80, 12.51, 6.92, 48.30, 11.10, 4.01 and 4.29, respectively, Z=-8.76; all P<0.05). Binary logistic regression analysis revealed that older age (odds ratio( OR)=1.057), comorbid chronic pulmonary diseases ( OR=2.998), diabetes ( OR=8.703), presence of dyspnea ( OR=5.132), and elevated D-dimer levels ( OR=1.672) were independent risk factors for PTE in PTB patients (all P<0.05). Conclusions:Older age, comorbid chronic pulmonary diseases, diabetes, dyspnea and elevated D-dimer levels are risk factors for PTE in PTB patients. Clinicians should remain vigilant to these factors to reduce the risk of missing PTE in this population.

To analyze the correlation of ADH4 exon rs1126671 and ADH7 exon rs971074 polymorphisms with risky drinking behaviors and alcoholic liver disease. The patients with alcoholic liver disease diagnosed in the Gastroenterology Department of the People′s Hospital of Hechi from November 2021 to June 2022, including 52 cases of alcoholic liver disease with positive risky drinking behaviors, 103 cases of non-alcoholic liver disease with positive risky drinking behaviors of the same gender and age, and 105 healthy subjects with no risky drinking behaviors as control groups were retrospectively analyzed. The serum total protein and albumin are detected by immunoturbidimetry and globulin is calculated by the difference method; the serum total bilirubin and direct bilirubin are detected by the nitrite oxidation method and indirect bilirubin is calculated by the difference method; alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and γ-glutamyl transferase are detected by the substrate method. The results revealed that all 52 patients with alcoholic liver disease were male. The non-parametric independent sample Kruskal-Wallis test was adopted to analyze the baseline of twelve liver functions among the alcoholic liver disease group, the risky drinking behavior group and the healthy control group, and it was found there was statistical significance in ten major liver function indicators in the difference comparison among the three groups like serum total protein (g/L) 65.0 (60.1, 71.4), 73.4 (70.3, 76.3), 72.4 (69.2, 76.2) ( H=37.130, P<0.001); albumin (g/L) 36.1 (28.6, 42.9), 47.2 (45.0, 49.2), 47.5 (45.9, 49.5) ( H=14.503, P=0.001); direct bilirubin (μmol/L) 10.1 (35.6, 34.0.1), 3.8 (3.1, 5.45), 4.2 (2.9, 6.0) ( H=26.608, P<0.001); alkaline phosphatase (U/L) 106.0 (71.0, 164.0), 68.0 (57.5, 82.0), 70.0 (59.0, 87.0) ( H=27.904, P<0.001); albumin to globulin 1.34 (0.91, 1.88), 1.82 (1.65, 2.00), 1.89 (1.68, 2.07) ( H=11.047, P=0.004); direct bilirubin to indirect bilirubin 0.91 (0.69, 1.91), 0.41 (0.35, 0.54), 0.42 (0.34, 0.54) ( H=19.478, P<0.001); serum total bilirubin (μmol/L) 23.9 (13.7, 51.0), 13.8 (10.2, 17.9), 13.0 (10.1, 17.4) ( H=18.375, P<0.001); aspartate aminotransferase (U/L) 74.0 (39.0, 122.0), 22.0 (19.0, 28.0), 23.0 (19.0, 30.0) ( H=76.365, P<0.001); alanine aminotransferase (U/L) 37.0 (25.0, 55.0), 23.0 (17.0, 30.0), 24.0 (17.0, 33.8) ( H=57.041, P<0.001); γ-glutamyl transferase (U/L) 135.0 (45.0, 364.0), 33.0 (23.5, 49.5), 32.0 (19.0, 49.0) ( H=82.558, P<0.001); however, there were no statistical significance in the pairwise comparisons between risky drinking and healthy groups. The two loci of ADH4 and ADH7 were in genetic linkage equilibrium. In the three groups of samples, the ADH4 gene rs1126671 locus was comprised primarily of the CC homozygous genotype, and there was no TT genotype. The ADH7 gene rs971074 genotype had statistical difference in the comparison of the three groups ( χ2=9.370, P<0.05). Compared with the CC genotype, the CT genotype had no statistical difference in the pairwise comparison between the risky drinking behavior group and alcoholic liver disease group, and the healthy group and alcoholic liver disease group. There was a statistical difference in that between the healthy group and the risky drinking behavior group ( χ2=6.372, P=0.012). The analysis display of mode of inheritance between RD group and HA group was statistically significant in the difference of the superdominance inheritance mode ( OR=2.92, 95% CI:1.22-6.98; P=0.012), the dominant inheritance mode ( OR=2.90, 95% CI:1.26-6.64; P=0.008), the co-dominant inheritance mode ( OR=2.96, 95% CI:1.24-7.08; P=0.032) and the additive mode ( OR=2.46, 95% CI:1.16-5.22; P=0.013). In general, the CT genotype of ADH7 gene rs971074 is a risk factor for positive risky drinking behavior, and the ADH family may still increase the susceptibility of people with a potential alcoholic liver disease protection background through the correlation between ADH7 and risky drinking behavior.

To analyze the correlation of ADH4 exon rs1126671 and ADH7 exon rs971074 polymorphisms with risky drinking behaviors and alcoholic liver disease. The patients with alcoholic liver disease diagnosed in the Gastroenterology Department of the People′s Hospital of Hechi from November 2021 to June 2022, including 52 cases of alcoholic liver disease with positive risky drinking behaviors, 103 cases of non-alcoholic liver disease with positive risky drinking behaviors of the same gender and age, and 105 healthy subjects with no risky drinking behaviors as control groups were retrospectively analyzed. The serum total protein and albumin are detected by immunoturbidimetry and globulin is calculated by the difference method; the serum total bilirubin and direct bilirubin are detected by the nitrite oxidation method and indirect bilirubin is calculated by the difference method; alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and γ-glutamyl transferase are detected by the substrate method. The results revealed that all 52 patients with alcoholic liver disease were male. The non-parametric independent sample Kruskal-Wallis test was adopted to analyze the baseline of twelve liver functions among the alcoholic liver disease group, the risky drinking behavior group and the healthy control group, and it was found there was statistical significance in ten major liver function indicators in the difference comparison among the three groups like serum total protein (g/L) 65.0 (60.1, 71.4), 73.4 (70.3, 76.3), 72.4 (69.2, 76.2) ( H=37.130, P<0.001); albumin (g/L) 36.1 (28.6, 42.9), 47.2 (45.0, 49.2), 47.5 (45.9, 49.5) ( H=14.503, P=0.001); direct bilirubin (μmol/L) 10.1 (35.6, 34.0.1), 3.8 (3.1, 5.45), 4.2 (2.9, 6.0) ( H=26.608, P<0.001); alkaline phosphatase (U/L) 106.0 (71.0, 164.0), 68.0 (57.5, 82.0), 70.0 (59.0, 87.0) ( H=27.904, P<0.001); albumin to globulin 1.34 (0.91, 1.88), 1.82 (1.65, 2.00), 1.89 (1.68, 2.07) ( H=11.047, P=0.004); direct bilirubin to indirect bilirubin 0.91 (0.69, 1.91), 0.41 (0.35, 0.54), 0.42 (0.34, 0.54) ( H=19.478, P<0.001); serum total bilirubin (μmol/L) 23.9 (13.7, 51.0), 13.8 (10.2, 17.9), 13.0 (10.1, 17.4) ( H=18.375, P<0.001); aspartate aminotransferase (U/L) 74.0 (39.0, 122.0), 22.0 (19.0, 28.0), 23.0 (19.0, 30.0) ( H=76.365, P<0.001); alanine aminotransferase (U/L) 37.0 (25.0, 55.0), 23.0 (17.0, 30.0), 24.0 (17.0, 33.8) ( H=57.041, P<0.001); γ-glutamyl transferase (U/L) 135.0 (45.0, 364.0), 33.0 (23.5, 49.5), 32.0 (19.0, 49.0) ( H=82.558, P<0.001); however, there were no statistical significance in the pairwise comparisons between risky drinking and healthy groups. The two loci of ADH4 and ADH7 were in genetic linkage equilibrium. In the three groups of samples, the ADH4 gene rs1126671 locus was comprised primarily of the CC homozygous genotype, and there was no TT genotype. The ADH7 gene rs971074 genotype had statistical difference in the comparison of the three groups ( χ2=9.370, P<0.05). Compared with the CC genotype, the CT genotype had no statistical difference in the pairwise comparison between the risky drinking behavior group and alcoholic liver disease group, and the healthy group and alcoholic liver disease group. There was a statistical difference in that between the healthy group and the risky drinking behavior group ( χ2=6.372, P=0.012). The analysis display of mode of inheritance between RD group and HA group was statistically significant in the difference of the superdominance inheritance mode ( OR=2.92, 95% CI:1.22-6.98; P=0.012), the dominant inheritance mode ( OR=2.90, 95% CI:1.26-6.64; P=0.008), the co-dominant inheritance mode ( OR=2.96, 95% CI:1.24-7.08; P=0.032) and the additive mode ( OR=2.46, 95% CI:1.16-5.22; P=0.013). In general, the CT genotype of ADH7 gene rs971074 is a risk factor for positive risky drinking behavior, and the ADH family may still increase the susceptibility of people with a potential alcoholic liver disease protection background through the correlation between ADH7 and risky drinking behavior.

Objective:To analyze the risk factors of pulmonary thromboembolism (PTE) in patients with pulmonary tuberculosis (PTB), to improve the awareness of clinicians.Methods:A total of 120 PTB patients complicated with PTE (PTE group) and 120 PTB patients without PTB (control group) admitted to the Affiliated Hospital of Zunyi Medical University from January 2018 to December 2022 were included. Clinical data from both groups were collected and compared. Statistical analyses were performed using the chi-square tests and Mann-Whitney U test, and binary logistic regression analysis was performed to identify the risk factors for PTE in PTB patients. Results:The age of the PTE group was 69.00(63.00, 76.75) years. The rates of comorbid chronic pulmonary diseases, respiratory failure, and diabetes in PTE group were 40.00%(48/120), 24.17%(29/120), and 12.50%(15/120), respectively.The incidence rates of dyspnea, chest distress, chest pain, and palpitations in PTE group were 80.83%(97/120), 21.67%(26/120), 23.33%(28/120), and 10.00%(12/120), respectively. The D-dimer level in PTE group was 3.34 (2.05, 6.60) mg/L. These results were all higher than those in the control group (10.00%(12/120), 7.50%(9/120), 3.33%(4/120), 36.67%(44/120), 6.67%(8/120), 13.33%(16/120), 3.33%(4/120), and 0.97(0.41, 2.11) mg/L, respectively). The differences were all statistically significant ( χ2=28.80, 12.51, 6.92, 48.30, 11.10, 4.01 and 4.29, respectively, Z=-8.76; all P<0.05). Binary logistic regression analysis revealed that older age (odds ratio( OR)=1.057), comorbid chronic pulmonary diseases ( OR=2.998), diabetes ( OR=8.703), presence of dyspnea ( OR=5.132), and elevated D-dimer levels ( OR=1.672) were independent risk factors for PTE in PTB patients (all P<0.05). Conclusions:Older age, comorbid chronic pulmonary diseases, diabetes, dyspnea and elevated D-dimer levels are risk factors for PTE in PTB patients. Clinicians should remain vigilant to these factors to reduce the risk of missing PTE in this population.

Ischemic stroke(IS)is the main cause of neurological dysfunction in adults in China,and rapid,timely,and accurate prediction of post-stroke outcome and intervention treatment are crucial.Currently,the prognosis of ischemic stroke mainly relies on neuroimaging and clinical assessment,and there is still a lack of objective and simple rapid prediction tools.Recent studies have shown that early measurement of peripheral blood-derived biomarkers may be able to predict stroke patient outcomes,thereby optimizing stroke management,improving patient rehabilitation,and improving stroke outcomes.This article reviews the progress of studies on the correlation between peripheral blood biomarkers and clinical prognosis of ischemic stroke.

Enteric-soluble soft capsule is a kind of new preparation that does not disintegrate in the stomach ，but releases rapidly in the intestinal tract to play a pharmacodynamic role. It has the unique advantages of improving drug stability ，reducing drug irritation ，delivering drugs directionally to the intestinal tract ，and prolonging drug action time. In this paper ，the decomposition and release mechanism ，application advantages ，classification of enteric-soluble coating materials and preparation methods of enteric-soluble soft capsule are sorted and summarized ，in order to provide reference for further development of this type of preparation.

Objective:To explore whether the adoption of high-flow nasal cannula (HFNC) as an initial oxygen therapy in emergency department (ED) could reduce the intubation rate and improve the clinical outcomes of patients with dyspnea and hypoxemia compared with conventional oxygen therapy (COT).Methods:A perspective single-center randomized controlled trial was conducted in the First Affiliated Hospital of Zhengzhou University from October 1, 2019 to September 30, 2020. A total of 210 eligible patients with acute dyspnea and hypoxemia in ED were recruited and randomized (in 1:1) to receive HFNC or COT for 1 h immediately after the grouping. The primary outcome was the rate of intubation within 24 h. The secondary outcomes included total intubation rate, escalation of breathing support method, patients’ disposition, length of ICU stay and hospital mortality. Continuous outcomes were analyzed by independent samples t test or Mann-Whitney U test according to the data distribution. Discontinuous outcomes were compared with the Chi-square test. Kaplan-Meier curve analysis was performed for 60-day survival. Results:Finally, 105 patients were recruited in each group. HFNC reduced the intubation rate within the first 24 h (4.8% vs. 14.3%, P = 0.019) and the rate of patients escalated to upgrade oxygen therapy (34.3% vs. 53.3%, P = 0.005), but did not affect the total intubation rate during the whole attendance ( P = 0.509). In ED, HFNC helped more patients to achieve the targeted saturation of pulse oxygen (90.5% vs. 78.1%, P = 0.02), and reduced respiratory rate (RR) to < 25 breaths per min (68.6% vs. 49.0%, P = 0.004), but did not affect the length of hospital stay, hospital mortality and 60-day survival rate ( P > 0.05). Conclusions:Initial application of HFNC in ED could reduce the intubation rate within 24 h, decrease the rate of escalation of oxygen therapy, improve oxygenation and relieve dyspnea.

Objective:To explore the effect of inpatient palliative care in patients with end-stage heart failure.Methods:From July 2019 to January 2021, convenience sampling was used to select 97 patients with end-stage heart failure admitted to the Cardiovascular Department of Henan Provincial Chest Hospital as the research subject. The patients were divided into the control group ( n=48) and the observation group ( n=49) with the random number table. The control group conducted routine nursing, and the observation group carried out inpatient palliative care on this basis. The 21-Item Depression Anxiety Stress Scale (DASS-21) , General Self-efficacy Scale (GSES) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) were used to compare the adverse psychological state, self-efficacy and quality of life of the two groups of patients. Results:Before intervention, there were no significant differences in DASS-21, MLHFQ and GSES scores between the two groups ( P>0.05) . After intervention, the DASS-21 and MLHFQ scores of the observation group were lower than those of the control group, and the GSES score was higher than that of the control group, and the differences were statistically significant ( P<0.05) . Conclusions:Inpatient palliative care can effectively relieve the adverse psychological state of patients with end-stage heart failure and improve their self-efficacy and quality of life.